This case, manufacturer control number 2015-0171948 is a spontaneous report form a Regulatory Authority (GB-
MHRA-ADR 23136685) referring to a 71 Year-old Male patient.  The following event was reported: Progressive 
Multifocal Leucoencephalopathy.
Medical history included: 
Current conditions: CLL progression
Historical condition: Chemotherapy
Historical drugs: CHLORAMBUCIL; RITUXIMAB, CYCLOPHOSPHAMIDE, VINCRISTINE, PREDNISOLONE (R-
CVP) chemotherapy; FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (FCR) chemotherapy
Concomitant medications included RAMIPRIL, SIMVASTATIN, TAMSULOSIN, ASPIRIN, FINASTERIDE, 
FUROSEMIDE, OMEPRAZOLE.
On 19-Jan-2015, the patient started receiving Rituximab 850 mg every 2-4 weeks intravenously for treatment of 
CLL progression.
On 22-Jan-2015, the patient started receiving ZYDELIG 150 mg twice daily by mouth for treatment of CLL 
progression.
On 02-Apr-2015, the patient received the last dose of Rituximab.
On 16-Apr-2015, the patient experienced Progressive Multifocal Leucoencephalopathy. A brain biopsy confirmed 
the diagnosis.
On 17-Apr-2015, the patient received the last dose of Zydelig.
On (b) (6)  the patient expired.
Relevant laboratory/diagnostic tests included:
??-???-2015: Biopsy brain: confirmed diagnosis 
The outcome of the event of Progressive Multifocal Leucoencephalopathy was Fatal.
Action taken with study Zydelig and Rituximab was Drug Discontinued.
As per report, the event of Progressive Multifocal Leucoencephalopathy was assessed as Serious (Fatal).  Event 
Print Time: 13-JUN-2016 09:36 AM If a field is blank, there is no data for that field Page 353 of 457
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
Causality was not provided. An Alternative etiology was not provided for the event.
As per Gilead system, the event was also assessed as Serious (Medically Significant). As per Gilead, the event was
assessed as Related to Zydelig.
Date of Death: (b) (6)
It was unknown whether an autopsy was performed.
The initial report was received on 11-Sep-2015.
Follow-up information was received on 17-Sep-2015 from a physician via Medicines and Healthcare Products 
Regulatory Agency (GB-ROCHE-1633629): 
It was confirmed that the patient died due to the event of Progressive Multifocal Leucoencephalopathy whilst being 
treated with rituximab and idelalisib. 
Two Historical Drugs were confirmed and added to the E2B fields: Vincristine and Prednisolone (missing in initial 
E2B, but mentioned in original narrative). 
On 02-Apr-2015, the patient took the most recent dose of rituximab. 
Event Causality to Zydelig and Rituximab was Not Reported.
Action taken with Zydelig was updated to: Not Applicable (previously reported as Drug Withdrawn); although Zydelig
Drug Interrupted Date was still provided as: 17-Apr-2015.
Action taken with Rituximab was updated to: Not Applicable (previously reported as Drug Withdrawn).
This information was incorporated into the case.